ResVita Bio
PrivateLast Round
Grant
Sep 24, 2024
Total Funding Raised
$2.28M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ResVita Bio is a biotechnology company that develops treatments for skin diseases using synthetic biology. The company's proprietary platform utilizes genetically engineered bacteria, applied topically, to function as living cellular factories that deliver therapeutic proteins directly to the affected skin. This method, which they call "continuous protein therapy," is designed to provide sustained, targeted treatment while minimizing systemic side effects. ResVita Bio is focused on developing therapies for conditions such as Netherton Syndrome, a rare genetic skin disorder, and atopic dermatitis. The company was co-founded by CEO Dr. Amin Zargar and synthetic biology pioneer Dr. Jay Keasling. It has received multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) to advance its research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ResVita Bio Comparables
Compare ResVita Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MatriSys Bioscience | 85% | |
| Azitra, Inc. | 84% | |
| Revance | 77% | |
ResVita Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 24, 2024 | ||||
| Seed | Dec 6, 2023 | ||||
| Grant | Sep 18, 2023 | ||||
| Grant | Sep 20, 2022 |
ResVita Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| Pioneer Fund | Seed |
| NIH RADx | Grant |
| Gaingels | Seed |
| Berkeley Frontier Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 90% MoM.
- Jun 17, 2026
Monthly visitors increased 682% MoM.
ResVita Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ResVita Bio's valuation, stock price, and market status.